Chargement en cours...
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
An increasing number of innovative oncology monoclonal antibodies (mAbs) have been introduced into the global market, and biosimilar versions have now also been approved in Europe. Being complex to develop and difficult to manufacture, the biosimilar is a drug similar but not identical in physicoche...
Enregistré dans:
| Publié dans: | Int J Clin Pharm |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6132979/ https://ncbi.nlm.nih.gov/pubmed/30094558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11096-018-0709-6 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|